On Demand

Prof Janet Pope: reaction to Xeljanz symposium

Prof Pope

Professor Pope discusses the key take home messages on the latest JAK inhibitor data from the Pfizer RA symposium at EULAR, and the implications this data has for clinical management of RA patients.

On Demand

Dr Eduardo Mysler: onset of action and sustained efficacy

Dr Mysler

Dr Eduardo Mysler discusses the onset of action and sustained efficacy

On Demand

TKI to TKI sequencing in mRCC: a case study

Dr Emilio Porfiri

For prescribing information and adverse event reporting please see the link in the information panel on the RHS of this page.

This case study demonstrates how axitinib in 2nd line mRCC can be used as part of a successful treatment sequence, followed by immunotherapy in the third line setting. It also highlights that treatment with axitinib following cardiac failure may be safely resumed on an individual patient basis  and provide long-term benefit following dose reduction.

On Demand

Efficacy and safety of axitinib following quick progression in 1st line: a case study

Dr Jason Lester

For prescribing information and adverse event reporting please see the link in the information panel on the RHS of this page.

This case study addresses how axitinib can be used as part of a successful treatment regime in patients with hypertension and following an acute medical event. This case study also demonstrates how to achieve an extended duration of treatment with axitinib irrespective of duration of first line therapy.

On Demand

Axitinib case study: integrated modality treatment for mRCC

Dr Kate Fife

For prescribing information and adverse event reporting please see the link in the information panel on the RHS of this page.

This case study highlights the importance of intra- and inter-patient variability and of dose individualization with axitinib to achieve disease control and maintain quality of life. It also addresses how challenging local mRCC may be managed using a multimodality approach of TKIs, radiotherapy and surgery.